Friday, May 22, 2009

So WHO is learning Water-Cure Protocol Formula too.

To World Health Organization (WHO,193 Member States) Director-General, Dr Margaret Chan and staff, kindly inform the world that water-cure protocol formula can beat many diseases.

Water-Cure Protocol Formula :
1.Drink 10 percent of your own daily water quota, which is 31.42 ml multiply by your present body weight (in kilogram), every 90 minute.

2. Use 1/4 teaspoon of sea-salt in your daily diet, for every 1250 ml water intake.

3.More details at or blog site Healthy Wealth :

Sincerely yours,
global active citizenry,
see choo soong

Human infection with new influenza A (H1N1) virus: clinical observations from Mexico and other affected countries, May 2009.

As of 20 May 2009, 10 243 laboratory-confirmed cases of new influenza A (H1N1) virus infection, including 80 deaths, had been reported to WHO from 41 countries.

Most of these cases were from North America (USA, 5469; Mexico, 3734; Canada,

The majority of fatal cases (74) were reported from Mexico .

This article summarizes the clinical features of human infection with new influenza A (H1N1) virus and provides initial WHO guidance on clinical management.

Clinical features
The spectrum of disease caused by new influenza A (H1N1) virus infection ranges from non-febrile, mild upper-respiratory tract illness to severe or fatal pneumonia.

Most cases appear to have uncomplicated, typical influenza-like illness and recover spontaneously. To prove the effective of any protocol, drug/drugs should not be prescribed for first 36 hours but only Saline IV, to confirm that it is the body systems which recover on its course.

The most commonly reported symptoms include cough, fever, sore throat, malaise and headache .

Fever has been absent in some outpatients and in up to 1 in 6 surviving hospitalized patients.

Gastrointestinal symptoms (nausea, vomiting and/or diarrhea) have occurred in up to 38% of outpatients in the United States.

Hospitalized patients. Approximately 2–5% of confirmed cases in the United States and Canada, as well as 6% in Mexico, have been admitted to hospital.

Among patients presenting with acute respiratory illness for care in Mexico, 13% tested positive for new influenza A (H1N1) virus infection (about one-fifth have had seasonal influenza), of whom about 10% have been hospitalized and one-third of those hospitalized required mechanical ventilation.

Almost one-half of the patients hospitalized in the United States, and 21 of 45 (46%) fatal cases in Mexico for whom data are available, have had underlying conditions, including pregnancy, asthma, other lung diseases, diabetes, morbid obesity, autoimmune disorders and associated immunosuppressive therapies, neurological disorders and cardiovascular disease. These conditions were initially due to cellular dehydration.

Among 20 pregnant women in the United States confirmed to have been infected with new influenza A (H1N1) virus, 3 required hospitalization, 1 of whom died; this patient had started antiviral therapy 13 days after illness onset.

Among 30 patients hospitalized in California, 64% had underlying conditions and 2 of 5 pregnant women developed complications, including spontaneous abortion and premature rupture of membranes.

Among 45 fatal cases in Mexico, 54% were among previously healthy people, most of whom were aged 20–59 years; 1 was a pregnant woman at 34 weeks’ gestation.

Case fatality ratios were lower in children and teenagers than in adults, for reasons to be determined. Rapidly progressive respiratory disease has accounted for most severe or fatal cases.

In Mexico, the median time from onset of illness to hospitalization was 6 days (range, 1–20 days) in 45 fatal cases, compared with a median of 4 days in hospitalized cases in the United States.

In fatal cases, the presenting manifestations have included fever, shortness of breath, myalgia, severe malaise, tachycardia, tachypnoea, low oxygen saturation and, sometimes, hypotension and cyanosis.

Several patients experienced cardiopulmonary arrest shortly after arrival at hospital.

Diarrhoea has been uncommon in hospitalized cases.

In Mexico, the clinical course has been notable for severe pneumonia, multifocal infiltrates including nodular alveolar and, less frequently, basilar opacities on chest radiographs, as well as rapid progression to acute respiratory distress syndrome (ARDS) and renal or multi-organ failure (24% of fatal cases).

The median time from symptom onset to death was 10 days (range, 2–33 days).

Of those hospitalized in California, 15 of 25 (60%) tested had radiographic changes suggestive of pneumonia, including 10 with multilobar infiltrates; 4 (13%) required mechanical ventilation.

Both leukocytosis and leucopenia have been found in those hospitalized.

In Mexico, many hospitalized patients have manifested lymphopenia, elevated aminotransferases, elevated lactate dehydrogenase (100% of 16 fatal cases) and, in some, very high levels of creatinine phosphokinase.

Up to one-half of hospitalized patients have shown some degree of renal insufficiency, perhaps secondary to rhabdomyolysis and myoglobinuria, although other causes including hypotension, dehydration and hypoxia may be contributory.

Acute myocarditis has been suspected in some patients, but encephalitis has not been described to date.

Microbiology and pathogenesis

Few patients have had evidence of bacterial infection upon admission, but instances of empyema, necrotizing pneumonia and bacterial coinfection, as well as ventilator-associated pneumonias, have occurred.

Some cases had received antibiotic treatment before hospitalization.

In Mexico, bacterial coinfections were documented in 3 fatal cases.

Preliminary studies utilizing molecular detection methods found 2 instances of coinfections (1 Streptococcus pneumoniae, 1 adenovirus) among 21 severe or fatal cases.

Initial autopsy reports from Mexico indicate that the pathology was consistent with ARDS secondary to primary viral pneumonia, including diffuse alveolar damage, peribronchiolar and perivascular lymphocytic infiltrates, hyperplastic airway changes and bronchiolitis obliterans. Muscle biopsies performed in 2 cases showed skeletal muscle necrosis.

Beware of scams implying association with WHO

Please note:

* WHO never asks for money for recruitment.
* WHO never charges registration fees for conferences or meetings.
* WHO does not conduct lotteries, or offer prizes or awards through e-mail.
* You can report any suspicious e-mail or web site to

Various fraudulent schemes purporting to be from or associated with the World Health Organization (WHO), have been circulating. Most of them circulate as e-mails, but there are also rogue web sites and in some instances faxes and telephones are used. Many of these scams request detailed information and/or money from individuals, businesses or non-profit organizations with the promise that they will receive funds or other benefits in return. Others ask for registration fees for conferences allegedly sponsored by WHO and for hotel reservations, again with the promise of certain benefits. Another type of scam proposes employment opportunities with WHO. These scams sometimes carry the WHO logo, and originate from or refer to e-mail addresses made to look like WHO or United Nations address.

WHO wishes to warn the public of these misleading practices that do not originate from WHO, and are not in any way associated with WHO projects or events. WHO strongly recommends that recipients of solicitations such as those described above (whether sent by e-mail or communicated in any other way) verify very carefully their authenticity before sending any response.

In particular, WHO suggests that recipients do not send money or personal information in response to invitations from anyone who claims to be awarding jobs, funds, grants, scholarships, certificates, lottery winnings, or prizes, and/or who requests payment for registration fees and hotel rooms reservations in the name of WHO. It is not a WHO policy to charge for attendance at meetings.

You can report any suspicious e-mail, letter or phone call purportedly from, for or on behalf of WHO, at WHO is trying to warn the community at large about these deceptive practices, and we will therefore appreciate your help in bringing suspect communications to our attention.

1 comment:

Steve Berke said...

I enjoyed reading your article :) PLease continue publishing helpful topics like this. Regards, from CWR, a company whose into selling water filtration systems that remove fluoride.

I think this How to remove Fluoride from water will fully complement your article.